Clinical Trial

AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive consolidation.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-05-31; most recent amendment 2022-08-18.
Status change: Not Yet Recruiting → Recruiting 2022-08-18
Trial Details
NCT Number NCT05404906
Lead Sponsor The First Affiliated Hospital of Soochow University
Conditions Acute Myeloid Leukemia (AML) in Remission
Enrollment 124 participants
Start Date 2022-06-25
Primary Completion 2028-06 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2022-08-19